Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Food & drink

Darden Restaurants, Pandora Media, Omeros Corp and more - PRE-MARKET

Proactive takes a look at the pre-market trade in New York and picks some highlights

US benchmarks are poised for a lower start, continuing the trajectory from yesterday's close.

Before the bell, shares in Darden Restaurants Inc (NYSE:DRI) are down 3.55% to US$90, despite its third quarter results exceeding Wall Street expectations.

The Orlando, Florida-based company said it had net income of US$1.73 per share, and adjusted for one-time gains and costs, that was US$1.71 per share. Consensus was for US$1.64 a share.

Meanwhile, Conagra Brands Inc (NYSE:CAG), the food packaging group, saw shares add 1.16% in pre-market to US$35.72 as its latest quarterly earnings report showed a profit beat and the group also raised its outlook.

Net income for the three months to February 25 rose to US$$362.8mln compared to US$179.7mln in the same period a year ago.

For fiscal 2018, Conagra raised its adjusted EPS (earnings per share) outlook to between US$2.03 and US$2.05 from its previous guidance of the higher end of US$1.84 to US$$1.89.

Elsewhere, Pandora Media Inc (NYSE:P) shares are up 5.92% to US$5.19 in deals before the bell. It came as wealth management group Raymond James upgraded the group to a 'strong buy' from 'market perform'.

Last but not least, Omeros Corp (NASDAQ:OMER) saw shares spike over 37% to US$16.03 as it was reported that the small drugs firm received a favorable ruling from the Congress.

Namely, an extra two years of charging Medicare higher prices for its cataract surgery drug.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK